Moxonidine for Prevention of Post-ablation AFib Recurrences
Status:
Completed
Trial end date:
2014-04-01
Target enrollment:
Participant gender:
Summary
Hypothesis: Modulation of central nervous sympathetic activation by administration of
moxonidine, a centrally acting medication which decreases the sympathetic nervous system
activity, can lead to a decrease in atrial fibrillation recurrence after ablation treatment
with pulmonary vein isolation.